BEFORE THE SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC

In the Matter of the Application of

Eyecity.com, Inc.

For Review of Denial of Company-Related Action by

Financial Industry Regulatory Authority

File No. 3-19239

FINRA'S MOTION TO DISMISS EYECITY.COM, INC.'S APPLICATION FOR REVIEW AND TO STAY BRIEFING SCHEDULE

Alan Lawhead
Vice President and
Director – Appellate Group

Jennifer Brooks Associate General Counsel

FINRA
Office of General Counsel
1735 K Street, NW
Washington, DC 20006
202-728-8083

July 11, 2019

RECEIVED JUL 11 2019 OFFICE OF THE SECRETARY

BEFORE THE SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC

In the Matter of the Application of

Eyecity.com, Inc.

For Review of Denial of Company-Related Actions by

Financial Industry Regulatory Authority

File No. 3-19239

FINRA'S MOTION TO DISMISS EYECITY.COM, INC.'S APPLICATION FOR REVIEW AND TO STAY BRIEFING SCHEDULE

I. INTRODUCTION

This matter concerns FINRA's Department of Market Operations ("Department") determination not to process documentation related to company-related actions for Eyecity.com, Inc., and the company's attempt to appeal to the Commission an initial decision by FINRA staff. The Department specifically determined that Eyecity.com's requests were deficient because FINRA has actual knowledge that the issuer is not current in its reporting requirements. In response, on June 27, 2019, Eyecity.com filed an appeal with FINRA's Uniform Practice Code Committee and—with no valid reason—a contemporaneous application for review with the Commission. RP 479-80, 685-86. The Commission should dismiss Eyecity.com's application

[&]quot;RP" refers to the page numbers in the certified record of this case filed with the Commission.

for review because FINRA has not issued a final decision and, therefore, Eyecity.com has failed to exhaust the administrative remedies available to it in FINRA's forum.²

II. BACKGROUND

A. FINRA Reviews Company-Related Actions

FINRA performs critical functions in the over-the-counter market. See Order Approving Proposed FINRA Rule 6490 (Processing of Company-Related Actions) ("Approval Order"), Exchange Act Release No. 62434, 2010 SEC LEXIS 2186, at *2-3 (July 1, 2010). FINRA reviews and processes requests to announce or publish company actions taken by issuers of overthe-counter securities to foster cooperation and coordination of the clearing, settling, and processing of transactions involving these securities, and in general, to protect investors and the public interest. See FINRA Rule 6490(a)(1). Specifically, FINRA reviews and processes documents relating to announcements for two categories of issuer actions: actions related to announcements required under Securities Exchange Act of 1934 Rule 10b-17 and "Other Company-Related Actions" (collectively, "Company-Related Actions"). Id. These Company-Related Actions include: (1) dividend payments or other distributions in cash or kind; (2) stock splits; (3) reverse stock splits; (4) rights or other subscription offerings; (5) any issuance or change to an issuer's symbol or name; (6) mergers; (7) acquisitions; (8) dissolutions; (9) bankruptcy; (10) liquidations; or (11) any other company control transaction. See FINRA Rule 6490(a)(2).

Pursuant to Commission Rule of Practice 161, FINRA requests that the Commission stay issuance of a briefing schedule in this matter while this motion is pending. See 17 C.F.R. § 201.161. The Commission should first evaluate the dispositive argument that Eyecity.com's appeal should be dismissed on procedural grounds before it reaches the underlying substance of this appeal.

In considering an issuer's request to process a Company-Related Action, the Department may request any necessary additional information to complete its review of the request. *See* FINRA Rule 6490(b)(4); *Approval Order*, 2010 SEC LEXIS 2186, at *9. If the Department determines to process documentation related to a Company-Related Action,³ the Department provides notice of the action to the over-the-counter market and adjusts the issuer's name, symbol, or stock price, as requested in the Company-Related Action. *See id.* at *4. The Department also publishes Company-Related Actions pursuant to requests from issuers and their agents on its website in a document known as the "Daily List." *See id.* at *4 n.7.

B. Deficiency Determinations Under FINRA Rule 6490

FINRA may determine that it is necessary for the protection of investors and in the public interest to deem a Company-Related Action deficient, in which case documentation related to the Company-Related Action will not be processed. FINRA Rule 6490(d)(3). Under FINRA Rule 6490, FINRA may deny an issuer's application for Company-Related Action based on five specific factors. *See id.* "The Rule's use of the permissive term 'may' vests FINRA with discretionary authority in deciding whether to process and announce a deficient Company-Related Action request on the OTCBB." *mPhase Technologies, Inc.*, Exchange Act Release No. 74187, 2015 SEC LEXIS 398, at *19-20 (Feb. 2, 2015). In this case, the Department denied

In addition to state corporate law requirements, an issuer with a class of publicly traded securities must comply with Exchange Act Rule 10b-17. See Approval Order, 2010 SEC LEXIS 2186, at *3 n.6. Exchange Act Rule 10b-17 requires that an issuer provide FINRA with notice of proposed Company-Related Actions when its securities are not listed on a national securities exchange or the SEC has not issued an exemption. See Exchange Act Rule 10b-17(a), (b)(2), (3); 17 C.F.R. 240.10b-17(a), (b)(2), (3). Once FINRA receives this notice, FINRA Rule 6490 authorizes FINRA to use its judgment and process or decline to process the Company-Related Action. See Approval Order, 2010 SEC LEXIS 2186, at *7.

Eyecity.com's requests pursuant to FINRA Rule 6490(d)(3)(2), because it determined that Eyecity.com is not current in its reporting requirements to the SEC. RP 465-66.

Following the Department's determination that an issuer's request is deficient because it falls within one or more of the five factors enumerated in FINRA Rule 6490(d)(3), the Department provides written notice of the deficiency to the issuer, identifying the specific factors that caused the request to be deemed deficient. *See Approval Order*, 2010 SEC LEXIS 2186, at *11; FINRA Rule 6490(d)(4). Once an issuer's request is deemed deficient, FINRA will not process the issuer's documentation for the proposed Company-Related Action or announce the Company-Related Action to the over-the-counter market. *See Approval Order*, 2010 SEC LEXIS 2186, at *9.

FINRA's review of a Company-Related Action includes an issuer's right to appeal.

FINRA Rule 6490 sets forth that an issuer has an exclusive right to appeal from a Department deficiency determination. See FINRA Rule 6490(e). A three-person subcommittee comprised of current or former industry members of FINRA's Uniform Practice Code Committee (the "UPC Subcommittee") reviews and decides all appeals. See FINRA Rule 6490(e). The UPC Subcommittee meets each month, as needed, and issues a written decision within three business days of its consideration of the appeal. See id. FINRA rules do not permit a direct appeal to the Commission of the Department's determination. Rather, it is the UPC Subcommittee's written decision that is the final FINRA action for purposes of an SEC appeal. Id.; see, e.g., mPhase,

The Uniform Practice Code provides the framework of rules governing broker-dealers for the settlement of non-exchange listed securities quoted or traded in the over-the-counter market. See Approval Order, 2010 SEC LEXIS 2186, at *5 n.8.

2015 SEC LEXIS 398, at *7-15 (illustrating that an issuer appealed to the Commission from UPC Subcommittee's decision affirming Department's decision).

III. FACTS

A. Eyecity.com Submits to FINRA the Notification of Company Related Actions

Eyecity.com is a natural resource exploration company with its core business focused on the precious metals mining sectors. "[I]ts business strategies are currently targeted towards junior mining companies that are in need of capital infusion, to expand production capabilities and advance proven properties." https://www.otcmarkets.com/stock/ICTY/profile (last visited July 10, 2019). Eyecity.com was seeking to effect a holding company reorganization and submitted the Issuer Company Related Action Notification on December 28, 2018. RP 1-7. Eyecity.com submitted its application requesting that FINRA process documentation related to a 1 for 74,000 reverse stock split in connection with a merger and name and symbol change. RP 3-4. As part of the Department's review, it asked Eyecity.com to answer a series of questions and provide documentation related to its requests. RP 85-88, 147-53,155-60, 197-205, 209-16, 355-65, 367-77, 409-22, 427-29, 431-41, 443-44. After reviewing the information that Eyecity.com provided, the Department deemed Eyecity.com's request deficient and denied the request. RP 465-68.

B. The Department Determines Eyecity.com's Request Is Deficient Under FINRA Rule 6490(d)(3)(2)

The Department denied Eyecity.com's request pursuant to FINRA Rule 6490(d)(3)(2). RP 465-66. The Department explained that it had actual knowledge that Eyecity.com is not current in its reporting requirements to the SEC. RP 465-66. The Department further explained that the issuer had failed to file 25 periodic reports from 2002 through 2008. RP 465-66. The Department concluded that as a result of Eyecity.com's lapses in meeting mandatory reporting

requirements, the issuer triggered one of the grounds delineated in FINRA Rule 6490(d)(3) and deemed the application deficient. RP 465-66. Consequently, the Department declined to process Eyecity.com's documentation concerning the reverse stock split and name and symbol change. RP 465. The Department provided Eyecity.com with a written deficiency determination on June 21, 2019. RP 465-68.

C. Eyecity.com Files Dueling Appeals with the UPC Subcommittee and the Commission

On June 27, 2019, Eyecity.com requested that the UPC Subcommittee review the Department's decision under FINRA Rule 6490(e). RP 479-80. On the same day that Eyecity.com appealed to the UPC Subcommittee, it also submitted an application for the Commission's review of the Department's deficiency decision. RP 685-86. Eyecity.com appealed to the Commission despite the fact that it had just asked the UPC Subcommittee to review this matter. *See* FINRA Rule 6490(e). On July 2, 2019, FINRA's Office of General Counsel notified the attorney representing the issuer that the appeal to the Commission at this stage of the case is not consistent with FINRA rules and requested that Eyecity.com withdraw its SEC appeal. RP 889-90. On July 3, 2019, Eyecity.com's counsel responded to FINRA's July 2 letter, admitting that the issuer is pursuing "remedies outside of the purview of the FINRA appeal process" by appealing to the SEC at this stage. RP 897. To date, Eyecity.com has not withdrawn its appeal to the Commission.

IV. ARGUMENT

The Commission should dismiss Eyecity.com's application for review because the issuer has failed to exhaust its administrative remedies under FINRA Rule 6490. FINRA procedures direct that the UPC Subcommittee conduct a de novo review of the record and issue a written decision before a Company-Related Action is considered a final action that is ripe for

Commission review. FINRA Rule 6490(e). At this stage of the proceeding, the Commission should decline to consider Eyecity.com's application for review because the issuer first must follow FINRA procedures to exhaust the available administrative remedies. *See WD Clearing, LLC*, Investment Co. Act Release No. 75868, 2015 SEC LEXIS 3699, at *20 (Sept. 9, 2015) ("If we were to assume that FINRA would have rejected Wilson-Davis's application based on the incomplete record before us, we would divest FINRA of its 'self-regulatory function' because FINRA did not have the opportunity to decide the issue for itself or review its own decision through its internal appellate process prior to Commission review.").

To properly invoke the Commission's review of a Company-Related Action denial,
Eyecity.com should appeal from a final FINRA action that denies its request, not an initial
determination from the Department. The UPC Subcommittee has not issued a final decision
and—while Eyecity.com's appeal to the Commission is pending—it will not. Eyecity.com
should withdraw this appeal, submit its arguments to the UPC Subcommittee, and receive a final
decision on its request. Eyecity.com can then evaluate if it is aggrieved by the UPC
Subcommittee's decision. At the moment, however, Eyecity.com has failed to take an appeal
that it must pursue to exhaust the remedies available to it.

As the Commission has emphasized, "[i]t is clearly proper to require that a statutory right to review be exercised in an orderly fashion, and to specify procedural steps which must be observed as a condition to securing review." *Ricky D. Mullins*, Exchange Act Release No. 71926, 2014 SEC LEXIS 1268, at *9 (Apr. 10, 2014) (citation omitted). The Commission has repeatedly held that requiring respondents to exhaust their administrative remedies before FINRA is necessary to FINRA's important regulatory functions, promotes development of the record, allows FINRA the opportunity to correct its own errors prior to Commission review, and

promotes the efficient resolution of disputes. *See, e.g., WD Clearing*, 2015 SEC LEXIS 3699, at *20; *Caryl Trewyn Lenahan*, Exchange Act Release No. 73146, 2014 SEC LEXIS 3503, at *5-7 (Sept. 19, 2014) (same); *Mullins*, 2014 SEC LEXIS 1268, at *10 (same).

Eyecity.com asserts that the Department "failed to provide a basis for [its] determination relative to the June 21, 2019 deficiency notice," and FINRA therefore did not provide the issuer with "sufficient information to properly pursue" an appeal to the UPC Subcommittee. RP 897. Eyecity.com is flat wrong. The Department's June 21 deficiency notice expressly states that FINRA has actual knowledge that the issuer is not current in its reporting requirements by failing to file 25 mandatory reports. RP 465-66. Consequently, and consistent with FINRA Rule 6490(d)(3), the Department determined that the issuer's request is deficient. RP 465-66.

Appellate review by the Commission here would be especially at odds with an orderly appeals process that "allow[s] the lower body to articulate its rationale or correct mistakes." Florence Sarah Pollard, Exchange Act Release No. 55978, 2007 SEC LEXIS 1430, at *7-8 (June 28, 2007); see also MFS Sec. Corp. v. SEC, 380 F.3d 611, 621 (2d Cir. 2004) (requiring applicant to exhaust administrative remedies "promotes the development of a record in a forum particularly suited to create it, upon which the Commission and, subsequently, the courts can more effectively conduct their review"), affirming MFS Sec. Corp., 56 S.E.C. 380, 393 (2003) (emphasizing that it is "clearly proper to require that a statutory right to review be exercised in an orderly fashion, and to specify procedural steps which must be observed as a condition to securing review" and refusing to consider applicant's denial of access to services claim because applicant failed to exhaust NYSE procedures). After its review, the UPC Subcommittee will issue a detailed written decision explaining the bases for its determination on appeal. See FINRA Rule 6490(e). Requiring the issuer to follow FINRA procedures and exhaust all of its

administrative remedies is consistent with Commission precedent and will promote the efficient resolution of this dispute. *See WD Clearing*, 2015 SEC LEXIS 3699, at *20. If the UPC Subcommittee's written decision is adverse to Eyecity.com, then the issuer within 30 days of service may appeal to the Commission. The issuer concedes as much. RP 898.

Regarding the key points of allowing an opportunity to correct errors and efficient resolution of SRO disputes, the Second Circuit Court of Appeals has explained:

Were SRO members, or former SRO members, free to bring their SRO-related grievances before the SEC without first exhausting SRO remedies, the self-regulatory function of SROs could be compromised. . . . It also provides SROs with the opportunity to correct their own errors prior to review by the Commission. The SEC's exhaustion requirement thus promotes the efficient resolution of disciplinary disputes between SROs and their members and is in harmony with Congress's delegation of authority to SROs to settle, in the first instance, disputes relating to their operations.

MFS Sec. Corp., 380 F.3d at 621-22. Thus, as an aggrieved party, Eyecity.com is required to exhaust its administrative remedies before resorting to an SEC appeal. Those who fail to exercise their rights to administrative review cannot claim that they have exhausted their administrative remedies. Royal Sec. Corp., 36 S.E.C. 275, 277 n.3 (1955).

In addition, the precedent with respect to administrative exhaustion is well-settled, and the Commission has consistently dismissed respondents' applications for review when respondents failed to exhaust their administrative remedies under FINRA rules. *See WD Clearing*, 2015 SEC LEXIS 3699, at *20 (requiring exhaustion before a firm can appeal a potential denial of membership); *see also Li-Lin Hsu*, Exchange Act Release No. 78899, 2016 SEC LEXIS 3585, at *6-14 (Sept. 21, 2016) (dismissing applicant's appeal for failure to exhaust administrative remedies when FINRA barred applicant under FINRA Rule 9552 for failing to respond to FINRA Rule 8210 requests); *Gerald J. Lodovico*, Exchange Act Release No. 73748, 2014 SEC LEXIS 4732, at *8 (Dec. 4, 2014) ("[The Commission] will not consider an

application for review if the applicant failed to exhaust FINRA's procedures."); *Pollard*, 2007 SEC LEXIS 1430, at *7 ("We decline to construe NASD rules in a way that would disturb the long-settled and well-justified policy of requiring people to exhaust the full administrative process at NASD. Prior to any appeal here, [appellant] was required to appeal the Remand Decision to the NAC.").

Instead of following the streamlined appellate process set forth in FINRA's rules, Eyecity.com filed this appeal with the Commission without a final FINRA decision. The issuer's failure to follow FINRA's procedure means that it does not qualify for appellate review by the Commission at this point in the process. *See WD Clearing*, 2015 SEC LEXIS 3699, at *20. The Commission, accordingly, should dismiss the application for review.

V. CONCLUSION

The Commission should dismiss Eyecity.com's appeal for its failure to exhaust FINRA's administrative remedies.

Respectfully submitted,

Jennifer Brooks

Associate General Counsel

FINRA

1735 K Street, NW

Washington, DC 20006

(202) 728-8083

July 11, 2019

CERTIFICATE OF SERVICE

I, Jennifer Brooks, certify that on this 11th day of July 2019, I caused a copy of FINRA's Motion to Dismiss the Application for Review and to Stay the Briefing Schedule, in the matter of <u>Application for Review of Eyecity.com</u>, <u>Inc.</u>, Administrative Proceeding No. 3-19239, to be served by messenger on:

Vanessa A. Countryman, Secretary Securities and Exchange Commission 100 F St., NE Room 10915 Washington, DC 20549-1090

and via FedEx, certified mail, and email on:

M. Richard Cutler, Esq.
Cutler Law Group PC
6575 West Loop South, Suite 500
Bellaire, TX 77401
rcutler@cutlerlaw.com

Service was made on the Commission by messenger and on the Applicant's attorney by FedEx, certified mail, and email due to the distance between the office of FINRA and the Applicant's attorney.

nnifer brooks

Associate General Counsel

FINRA

1735 K Street, NW

Washington, DC 20006

(202) 728-8083



Financial Industry Regulatory Authority

Jennifer Brooks

Associate General Counsel

Direct: (202) 728-8083

(202) 728-8264 Fax:

RECEIVED JUL 11 2019 OFFICE OF THE SECRETARY

July 11, 2019

VIA MESSENGER

Vanessa A. Countryman, Secretary Securities and Exchange Commission 100 F Street, NE Room 10915 Washington, DC 20549-1090

RE:

In the Matter of the Application for Review of Eyecity.com, Inc. (CareX

Blockchain Platform, Inc.)

Administrative Proceeding No. 3-19239

Dear Ms. Countryman:

Enclosed please find the original and three (3) copies of FINRA's Motion to Dismiss Eyecity.com, Inc.'s Application for Review and to Stay Briefing Schedule in the above-captioned matter.

Please contact me at (202) 728-8083 if you have any questions.

Very truly yours,

Jennifer Brooks

Enclosures

cc:

M. Richard Cutler, Esq. (via FedEx, certified mail, and email)

Cutler Law Group PC

6575 West Loop South, Suite 500

Bellaire, TX 77401 rcutler@cutlerlaw.com